

Early neuronal dysfunction by amyloid \hat{I}^2 oligomers depends on NR2B-containing NMDA receptors

Neurobiology of Aging

32, 2219-2228

DOI: [10.1016/j.neurobiolaging.2010.01.011](https://doi.org/10.1016/j.neurobiolaging.2010.01.011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	<i>N</i> -Methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid- β peptide oligomers. <i>Journal of Neurochemistry</i> , 2010, 115, 1520-1529.	2.1	141
2	Prolonged Exposure of Cortical Neurons to Oligomeric Amyloid- β Impairs NMDA Receptor Function Via NADPH Oxidase-Mediated ROS Production: Protective Effect of Green Tea (-)-Epigallocatechin-3-Gallate. <i>ASN Neuro</i> , 2010, 3, AN20100025.	1.5	81
3	ADDLs and the signaling web that leads to Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 230-242.	2.0	96
4	Soluble A β Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. <i>Journal of Neuroscience</i> , 2011, 31, 6627-6638.	1.7	530
5	The A β oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. <i>Neurobiology of Learning and Memory</i> , 2011, 96, 529-543.	1.0	386
6	Lipid Rafts: Linking Alzheimer's Amyloid- β Production, Aggregation, and Toxicity at Neuronal Membranes. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	1.1	156
7	Nuclear Translocation of Jacob in Hippocampal Neurons after Stimuli Inducing Long-Term Potentiation but Not Long-Term Depression. <i>PLoS ONE</i> , 2011, 6, e17276.	1.1	46
8	Between promiscuity and specificity: novel roles of EF-hand calcium sensors in neuronal Ca ²⁺ signalling. <i>Journal of Neurochemistry</i> , 2011, 118, 695-713.	2.1	53
9	Proteolysis of calcineurin is increased in human hippocampus during mild cognitive impairment and is stimulated by oligomeric Abeta in primary cell culture. <i>Aging Cell</i> , 2011, 10, 103-113.	3.0	41
10	Selective Hippocampal Neurodegeneration in Transgenic Mice Expressing Small Amounts of Truncated A β Is Induced by Pyroglutamate-A β Formation. <i>Journal of Neuroscience</i> , 2011, 31, 12790-12801.	1.7	90
11	Fyn, a Potential Target for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 243-252.	1.2	50
12	The Toxicity of Amyloid β Oligomers. <i>International Journal of Molecular Sciences</i> , 2012, 13, 7303-7327.	1.8	124
13	Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006312-a006312.	2.9	637
14	Postsynaptic Receptors for Amyloid- β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease. <i>Frontiers in Physiology</i> , 2012, 3, 464.	1.3	84
15	Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures. <i>Current Alzheimer Research</i> , 2012, 9, 844-856.	0.7	30
16	Alzheimer's disease, β -amyloid, glutamate, NMDA receptors and memantine – searching for the connections. <i>British Journal of Pharmacology</i> , 2012, 167, 324-352.	2.7	396
17	Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of β -Amyloid. <i>Journal of Neuroscience</i> , 2012, 32, 8767-8777.	1.7	219
18	Aging of the NMDA receptor: from a mouse's point of view. <i>Future Neurology</i> , 2012, 7, 627-637.	0.9	36

#	ARTICLE	IF	CITATIONS
19	Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity. <i>Journal of Molecular Biology</i> , 2012, 421, 427-440.	2.0	301
20	Alzheimer Mechanisms and Therapeutic Strategies. <i>Cell</i> , 2012, 148, 1204-1222.	13.5	1,548
21	Neuronal receptors as targets for the action of amyloid-beta protein (A β) in the brain. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e2.	1.6	46
22	N-terminal pyroglutamate formation of A β ²³⁸ and A β ²⁴⁰ enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. <i>Journal of Neurochemistry</i> , 2012, 121, 774-784.	2.1	76
23	NMDA receptors and BAX are essential for A β impairment of LTP. <i>Scientific Reports</i> , 2012, 2, 225.	1.6	38
24	New developments on the role of NMDA receptors in Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2012, 22, 559-563.	2.0	104
25	Effect of bFGF on neuronal damage induced by sequential treatment of amyloid β and excitatory amino acid in vitro and in vivo. <i>European Journal of Pharmacology</i> , 2012, 695, 76-82.	1.7	19
26	Laser-Induced Liquid Bead Ion Desorption Mass Spectrometry: An Approach to Precisely Monitor the Oligomerization of the β -Amyloid Peptide. <i>Analytical Chemistry</i> , 2012, 84, 5276-5284.	3.2	30
27	Selective Impairment of Some Forms of Synaptic Plasticity by Oligomeric Amyloid- β Peptide in the Mouse Hippocampus: Implication of Extrasynaptic NMDA Receptors. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 183-196.	1.2	37
28	Pyruvate Prevents the Inhibition of the Long-term Potentiation Induced by Amyloid- β through Protein Phosphatase 2A Inactivation. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 665-673.	1.2	23
29	Long-Distance Signaling from Synapse to Nucleus via Protein Messengers. <i>Advances in Experimental Medicine and Biology</i> , 2012, 970, 355-376.	0.8	15
31	Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 855-862.	1.3	84
32	Structural Basis of β -Amyloid-Dependent Synaptic Dysfunctions. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 1576-1579.	7.2	57
33	NMDA receptors in nervous system diseases. <i>Neuropharmacology</i> , 2013, 74, 69-75.	2.0	228
34	Protective effects of EphB2 on A β ¹⁻⁴² oligomer-induced neurotoxicity and synaptic NMDA receptor signaling in hippocampal neurons. <i>Neurochemistry International</i> , 2013, 63, 283-290.	1.9	27
35	Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid- β . <i>Neuroscience Bulletin</i> , 2013, 29, 752-760.	1.5	42
36	A β induces acute depression of excitatory glutamatergic synaptic transmission through distinct phosphatase-dependent mechanisms in rat CA1 pyramidal neurons. <i>Brain Research</i> , 2013, 1515, 88-97.	1.1	15
37	The role of β -secretase in hippocampal synaptic transmission and activity-dependent synaptic plasticity. <i>Neuroscience Letters</i> , 2013, 554, 16-21.	1.0	6

#	ARTICLE	IF	CITATIONS
38	Metabotropic NMDA receptor function is required for β -amyloid-induced synaptic depression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4033-4038.	3.3	154
39	Diversity in NMDA Receptor Composition. Neuroscientist, 2013, 19, 62-75.	2.6	340
40	β -Amyloid-aluminum complex alters cytoskeletal stability and increases ROS production in cortical neurons. Neurochemistry International, 2013, 62, 566-574.	1.9	20
41	Encoding and Transducing the Synaptic or Extrasynaptic Origin of NMDA Receptor Signals to the Nucleus. Cell, 2013, 152, 1119-1133.	13.5	173
42	Emerging roles of metaplasticity in behaviour and disease. Trends in Neurosciences, 2013, 36, 353-362.	4.2	164
43	NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nature Reviews Neuroscience, 2013, 14, 383-400.	4.9	1,928
44	Effects of different amyloid β -protein analogues on synaptic function. Neurobiology of Aging, 2013, 34, 1032-1044.	1.5	56
45	Cellular prion protein and Alzheimer disease. Prion, 2013, 7, 114-116.	0.9	11
46	Mass Transfer and Computational Fluid-dynamics in Bioreactors. , 2013, , 460-486.		0
47	Multiple effects of β -amyloid on single excitatory synaptic connections in the PFC. Frontiers in Cellular Neuroscience, 2013, 7, 129.	1.8	16
48	Amyloid Beta-Protein and Neural Network Dysfunction. Journal of Neurodegenerative Diseases, 2013, 2013, 1-8.	1.1	23
49	Enhanced Expression of NR2B Subunits of NMDA Receptors in the Inherited Glaucomatous DBA/2J Mouse Retina. Neural Plasticity, 2013, 2013, 1-7.	1.0	12
50	Inhibition of the Polyamine System Counteracts β -Amyloid Peptide-Induced Memory Impairment in Mice: Involvement of Extrasynaptic NMDA Receptors. PLoS ONE, 2014, 9, e99184.	1.1	45
51	Parkin overexpression ameliorates hippocampal long-term potentiation and β -amyloid load in an Alzheimer's disease mouse model. Human Molecular Genetics, 2014, 23, 1056-1072.	1.4	64
52	Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human A β -induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-A β agents. Acta Neuropathologica Communications, 2014, 2, 175.	2.4	32
53	STAT1 Negatively Regulates Spatial Memory Formation and Mediates the Memory-Impairing Effect of A β . Neuropsychopharmacology, 2014, 39, 746-758.	2.8	39
54	Chronic GluN2B Antagonism Disrupts Behavior in Wild-Type Mice Without Protecting Against Synapse Loss or Memory Impairment in Alzheimer's Disease Mouse Models. Journal of Neuroscience, 2014, 34, 8277-8288.	1.7	24
55	mGlu5 receptors and cellular prion protein mediate amyloid- β -facilitated synaptic long-term depression in vivo. Nature Communications, 2014, 5, 3374.	5.8	157

#	ARTICLE	IF	CITATIONS
56	Dysfunctional synapse in Alzheimer's disease – A focus on NMDA receptors. <i>Neuropharmacology</i> , 2014, 76, 16-26.	2.0	158
57	Cellular distribution of the NMDA-receptor activated synapto-nuclear messenger Jacob in the rat brain. <i>Brain Structure and Function</i> , 2014, 219, 843-860.	1.2	23
58	Reciprocal disruption of neuronal signaling and $A\beta$ production mediated by extrasynaptic NMDA receptors: a downward spiral. <i>Cell and Tissue Research</i> , 2014, 356, 279-286.	1.5	40
59	Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders. <i>Neuron</i> , 2014, 82, 279-293.	3.8	450
60	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S177-S187.	1.2	64
61	Nature of the neurotoxic membrane actions of amyloid- β on hippocampal neurons in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 472-481.	1.5	55
62	Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 4803-4813.	2.4	42
63	Oligomer-targeting with a conformational antibody fragment promotes toxicity in $A\beta$ -expressing flies. <i>Acta Neuropathologica Communications</i> , 2014, 2, 43.	2.4	10
64	A role for the neuroligin-neurexin complex in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 746-756.	1.5	42
65	Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease $A\beta$ <i>in vivo</i> . <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130147.	1.8	23
66	Iron overload accelerates neuronal amyloid- β production and cognitive impairment in transgenic mice model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2288-2301.	1.5	106
67	Disrupted cross-laminar cortical processing in β amyloid pathology precedes cell death. <i>Neurobiology of Disease</i> , 2014, 63, 62-73.	2.1	21
68	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease. <i>Neuron</i> , 2014, 82, 756-771.	3.8	862
69	Amyloid- β 1-42 Disrupts Synaptic Plasticity by Altering Glutamate Recycling at the Synapse. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 449-456.	1.2	39
70	Differential Effects of Palmitoylethanolamide against Amyloid- β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 407-421.	1.2	26
71	Effects of diazoxide on $A\beta$ 1-42-induced expression of the NR2B subunit in cultured cholinergic neurons. <i>Molecular Medicine Reports</i> , 2015, 12, 8301-8305.	1.1	1
72	Alzheimer's Disease: Mechanism and Approach to Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 26417-26451.	1.8	82
73	Calpain-Mediated Degradation of Drebrin by Excitotoxicity In vitro and In vivo. <i>PLoS ONE</i> , 2015, 10, e0125119.	1.1	28

#	ARTICLE	IF	CITATIONS
74	L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer's disease via activating dopamine D1 receptor/PKA signaling pathway. <i>Cell Death and Disease</i> , 2015, 6, e1965-e1965.	2.7	46
75	Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2015, 74, 254-262.	2.1	35
76	Leptin attenuates the detrimental effects of β -amyloid on spatial memory and hippocampal later-phase long term potentiation in rats. <i>Hormones and Behavior</i> , 2015, 73, 125-130.	1.0	36
77	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		0
78	The soluble extracellular fragment of neuroligin-1 targets $A\beta$ oligomers to the postsynaptic region of excitatory synapses. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 66-71.	1.0	23
79	Eph receptors: New players in Alzheimer's disease pathogenesis. <i>Neurobiology of Disease</i> , 2015, 73, 137-149.	2.1	34
80	Sigma-1 (σ 1) receptor deficiency reduces β -amyloid ₂₅₋₃₅ -induced hippocampal neuronal cell death and cognitive deficits through suppressing phosphorylation of the NMDA receptor NR2B. <i>Neuropharmacology</i> , 2015, 89, 215-224.	2.0	30
81	Stem Cell Therapy: A Prospective Treatment for Alzheimer's Disease. <i>Psychiatry Investigation</i> , 2016, 13, 583.	0.7	25
82	Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies. <i>Neural Plasticity</i> , 2016, 2016, 1-20.	1.0	111
83	Emerging Link between Alzheimer's Disease and Homeostatic Synaptic Plasticity. <i>Neural Plasticity</i> , 2016, 2016, 1-19.	1.0	67
84	Amyloid-Beta Induced Changes in Vesicular Transport of BDNF in Hippocampal Neurons. <i>Neural Plasticity</i> , 2016, 2016, 1-15.	1.0	26
85	Synaptic GluN2B/CaMKII β Signaling Induces Synapto-Nuclear Transport of ERK and Jacob. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 66.	1.4	25
86	A Jacob/Nsmf Gene Knockout Results in Hippocampal Dysplasia and Impaired BDNF Signaling in Dendritogenesis. <i>PLoS Genetics</i> , 2016, 12, e1005907.	1.5	36
87	Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β - and TNF α - Mediated Synaptic Plasticity Disruption in the Rat Hippocampus. <i>Cerebral Cortex</i> , 2017, 27, 3724-3735.	1.6	17
88	What do we learn from the murine Jacob/Nsmf gene knockout for human disease?. <i>Rare Diseases (Austin, Tex)</i> , 2016, 4, e1241361.	1.8	8
89	Differential Regulation of N-Methyl-D-Aspartate Receptor Subunits is An Early Event in the Actions of Soluble Amyloid- β ₁₋₄₀ Oligomers on Hippocampal Neurons. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 197-212.	1.2	22
90	Opposite <i>in vivo</i> effects of agents that stimulate or inhibit the glutamate/cysteine exchanger system on the inhibition of hippocampal LTP by A β . <i>Hippocampus</i> , 2016, 26, 1655-1665.	0.9	6
91	Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 11959-11973.	1.7	44

#	ARTICLE	IF	CITATIONS
92	When, where and how? Focus on neuronal calcium dysfunctions in Alzheimer's Disease. <i>Cell Calcium</i> , 2016, 60, 289-298.	1.1	31
93	Local and Use-Dependent Effects of β -Amyloid Oligomers on NMDA Receptor Function Revealed by Optical Quantal Analysis. <i>Journal of Neuroscience</i> , 2016, 36, 11532-11543.	1.7	46
94	Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors. <i>Nature Communications</i> , 2016, 7, 11915.	5.8	184
95	Dose-Dependent Neuroprotection and Neurotoxicity of Simvastatin through Reduction of Farnesyl Pyrophosphate in Mice Treated with Intracerebroventricular Injection of $A\beta$ 1-42. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 501-516.	1.2	14
96	Parishin C's prevention of $A\beta$ 42-induced inhibition of long-term potentiation is related to NMDA receptors. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 189-197.	5.7	29
97	Dopamine agonists rescue $A\beta$ -induced LTP impairment by Src-family tyrosine kinases. <i>Neurobiology of Aging</i> , 2016, 40, 98-102.	1.5	26
98	Roles of O-GlcNAcylation on amyloid- β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer's disease. <i>Neurological Research</i> , 2016, 38, 177-186.	0.6	18
99	Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function. <i>Neuron</i> , 2016, 89, 983-999.	3.8	138
100	Dysfunction of NMDA receptors in Alzheimer's disease. <i>Neurological Sciences</i> , 2016, 37, 1039-1047.	0.9	186
101	Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2760-2779.	2.9	84
102	The Essential Role of Soluble $A\beta$ Oligomers in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 1905-1924.	1.9	73
103	Involvement of GluN2B subunit containing N-methyl-D-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta ($A\beta$) in murine models of Alzheimer's disease (AD). <i>Neuropharmacology</i> , 2017, 123, 100-115.	2.0	29
104	Targeting glutamatergic and cellular prion protein mechanisms of amyloid β -mediated persistent synaptic plasticity disruption: Longitudinal studies. <i>Neuropharmacology</i> , 2017, 121, 231-246.	2.0	26
105	Posttranslational modification impact on the mechanism by which amyloid β induces synaptic dysfunction. <i>EMBO Reports</i> , 2017, 18, 962-981.	2.0	50
106	Metaplasticity mechanisms restore plasticity and associativity in an animal model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 5527-5532.	3.3	48
107	Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model. <i>Cell Death and Disease</i> , 2017, 8, e2717-e2717.	2.7	60
108	Modulating the Balance of Synaptic and Extrasynaptic NMDA Receptors Shows Positive Effects against Amyloid- β -Induced Neurotoxicity. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 885-897.	1.2	32
109	Amyloid beta: structure, biology and structure-based therapeutic development. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1205-1235.	2.8	1,094

#	ARTICLE	IF	CITATIONS
110	Epigenetic regulation by G9a/GLP complex ameliorates amyloid β 42 induced deficits in long-term plasticity and synaptic tagging/capture in hippocampal pyramidal neurons. <i>Aging Cell</i> , 2017, 16, 1062-1072.	3.0	34
111	SORLA attenuates EphA4 signaling and amyloid β 42-induced neurodegeneration. <i>Journal of Experimental Medicine</i> , 2017, 214, 3669-3685.	4.2	35
112	Diverse modes of NMDA receptor positive allosteric modulation: Mechanisms and consequences. <i>Neuropharmacology</i> , 2017, 112, 34-45.	2.0	76
113	Cholesterol and Fat Metabolism in Alzheimer's Disease. , 2017, , 161-193.		0
114	Chronic Monoarthritis Pain Accelerates the Processes of Cognitive Impairment and Increases the NMDAR Subunits NR2B in CA3 of Hippocampus from 5-month-old Transgenic APP/PS1 Mice. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 123.	1.7	26
115	Amyloid- β Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 202.	1.4	9
116	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease β 42. , 2017, , 65-135.		1
117	Fluorinated GluN2B Receptor Antagonists with a Benzazepine Scaffold Designed for PET Studies. <i>ChemMedChem</i> , 2018, 13, 1058-1068.	1.6	13
118	Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2018, 144, 672-681.	2.6	16
119	Synapse-to-nucleus communication: from developmental disorders to Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2018, 48, 160-166.	2.0	34
120	HIPK2-Mediated Transcriptional Control of NMDA Receptor Subunit Expression Regulates Neuronal Survival and Cell Death. <i>Journal of Neuroscience</i> , 2018, 38, 4006-4019.	1.7	28
121	DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2018, 827, 215-226.	1.7	49
122	Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia. <i>Brain, Behavior, and Immunity</i> , 2018, 67, 139-151.	2.0	99
123	Hippocampale synaptische Plastizität bei neurodegenerativen Erkrankungen: β 42, Tau und darüber hinaus. <i>Neuroforum</i> , 2018, 24, 203-212.	0.2	1
124	Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 963.	1.4	65
125	Astrocytic β 7 Nicotinic Receptor Activation Inhibits Amyloid- β Aggregation by Upregulating Endogenous β 2-microglobulin through the PI3K/Akt Signaling Pathway. <i>Current Alzheimer Research</i> , 2018, 16, 39-48.	0.7	21
126	Excitotoxicity. , 2018, , 70-100.		0
127	N-Methyl-D-Aspartate Receptor Link to the MAP Kinase Pathway in Cortical and Hippocampal Neurons and Microglia Is Dependent on Calcium Sensors and Is Blocked by β 2-Synuclein, Tau, and Phospho-Tau in Non-transgenic and Transgenic APPSw,Ind Mice. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 273.	1.4	19

#	ARTICLE	IF	CITATIONS
128	Commentary: GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 315.	1.4	2
129	Hippocampal synaptic plasticity in neurodegenerative diseases: A β , tau and beyond. <i>Neuroforum</i> , 2018, 24, A133-A141.	0.2	1
130	NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (A β) overexpressing mice. <i>Acta Neuropathologica Communications</i> , 2018, 6, 110.	2.4	26
131	The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer's Disease Therapeutics and Diagnostics. <i>Pharmaceutics</i> , 2018, 10, 190.	2.0	28
132	Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 307.	1.4	42
133	Effects of NMDAR Antagonist on the Regulation of P-MARCKS Protein to A β 1-42 Oligomers Induced Neurotoxicity. <i>Neurochemical Research</i> , 2018, 43, 2008-2015.	1.6	9
134	Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 397-404.	2.6	6
135	Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid β . <i>Frontiers in Pharmacology</i> , 2018, 9, 237.	1.6	54
136	Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42. <i>Molecules</i> , 2018, 23, 718.	1.7	20
137	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (A β) species on long-term potentiation (LTP). <i>Neuropharmacology</i> , 2018, 140, 184-192.	2.0	22
138	Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1176-1188.	2.5	71
139	CaMKII Metaplasticity Drives A β Oligomer-Mediated Synaptotoxicity. <i>Cell Reports</i> , 2018, 23, 3137-3145.	2.9	61
140	Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease. <i>Neurology</i> , 2018, 91, 125-132.	1.5	65
141	Senescent neurophysiology: Ca ²⁺ signaling from the membrane to the nucleus. <i>Neurobiology of Learning and Memory</i> , 2019, 164, 107064.	1.0	13
142	Paricalcitol accelerates BACE1 lysosomal degradation and inhibits calpain-1 dependent neuronal loss in APP/PS1 transgenic mice. <i>EBioMedicine</i> , 2019, 45, 393-407.	2.7	18
143	Acute and Chronic Sleep Deprivation-Related Changes in N-methyl-D-aspartate Receptor's Nitric Oxide Signalling in the Rat Cerebral Cortex with Reference to Aging and Brain Lateralization. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3273.	1.8	13
144	Synapse-to-Nucleus Signaling in Neurodegenerative and Neuropsychiatric Disorders. <i>Biological Psychiatry</i> , 2019, 86, 87-96.	0.7	24
145	Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3559-3567.	1.4	4

#	ARTICLE	IF	CITATIONS
146	Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 214-222.	1.4	15
147	Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. <i>Neurobiology of Disease</i> , 2019, 127, 605-615.	2.1	79
148	Amyloid- β^2 Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena. <i>Molecular Neurobiology</i> , 2019, 56, 7136-7143.	1.9	9
149	Hippocampal Mossy Fibers Synapses in CA3 Pyramidal Cells Are Altered at an Early Stage in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2019, 39, 4193-4205.	1.7	41
150	Ca ²⁺ homeostasis dysregulation in Alzheimer's disease: a focus on plasma membrane and cell organelles. <i>FASEB Journal</i> , 2019, 33, 6697-6712.	0.2	62
151	Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. <i>Frontiers in Neuroscience</i> , 2019, 13, 164.	1.4	221
152	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. <i>Neuropharmacology</i> , 2019, 151, 21-32.	2.0	7
153	Potential of NMDA-Mediated Responses by Amyloid- β^2 Peptide 1-40 in Rat Sympathetic Preganglionic Neurons. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1291-1303.	1.2	5
154	The Role of NMDA Receptors in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 43.	1.4	275
155	Tau- but not A β -pathology enhances NMDAR-dependent depotentiation in AD-mouse models. <i>Acta Neuropathologica Communications</i> , 2019, 7, 202.	2.4	0
156	Involvement of calpain in the neuropathogenesis of Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2019, 39, 608-630.	5.0	70
157	Intradomain Interactions in an NMDA Receptor Fragment Mediate N-Glycan Processing and Conformational Sampling. <i>Structure</i> , 2019, 27, 55-65.e3.	1.6	9
158	Calcium-Handling Defects and Neurodegenerative Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a035212.	2.3	55
159	Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer's Disease. <i>Cells</i> , 2020, 9, 2513.	1.8	22
160	Amyloid Beta Secreted during Consolidation Prevents Memory Malleability. <i>Current Biology</i> , 2020, 30, 1934-1940.e4.	1.8	13
161	The two faces of synaptic failure in AppNL-G-F knock-in mice. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 100.	3.0	25
162	Evaluation of 5 H ⁺ thiazolo[3,2-a]pyrimidin-5-ones as Potential GluN2A PET Tracers. <i>ChemMedChem</i> , 2020, 15, 2448-2461.	1.6	2
163	Novel huperzine A based NMDA antagonists: insights from molecular docking, ADME/T and molecular dynamics simulation studies. <i>RSC Advances</i> , 2020, 10, 25446-25455.	1.7	2

#	ARTICLE	IF	CITATIONS
164	Synaptic GluN2A-Containing NMDA Receptors: From Physiology to Pathological Synaptic Plasticity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1538.	1.8	69
165	A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca ²⁺ homeostasis in 3xTg-AD mice. <i>Neuropharmacology</i> , 2020, 170, 108042.	2.0	24
166	Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 90.	1.8	145
167	Amyloid- β^2 oligomers in cellular models of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 155, 348-369.	2.1	50
168	Roles of glutamate receptors in a novel in vitro model of early, comorbid cerebrovascular, and Alzheimer's diseases. <i>Journal of Neurochemistry</i> , 2021, 156, 539-552.	2.1	4
169	Differential inhibitory effects of resveratrol on excitotoxicity and synaptic plasticity: involvement of NMDA receptor subtypes. <i>Nutritional Neuroscience</i> , 2021, 24, 443-458.	1.5	6
170	A β^2 Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors. <i>ACS Chemical Neuroscience</i> , 2021, 12, 766-781.	1.7	35
171	Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2283.	1.8	39
172	A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer's Pathogenesis And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2140.	1.8	11
173	System-Level Analysis of Alzheimer's Disease Prioritizes Candidate Genes for Neurodegeneration. <i>Frontiers in Genetics</i> , 2021, 12, 625246.	1.1	9
174	NSMF promotes the replication stress-induced DNA damage response for genome maintenance. <i>Nucleic Acids Research</i> , 2021, 49, 5605-5622.	6.5	6
175	Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer's Disease. <i>Marine Drugs</i> , 2021, 19, 343.	2.2	8
176	Amyloid Beta-Mediated Changes in Synaptic Function and Spine Number of Neocortical Neurons Depend on NMDA Receptors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6298.	1.8	5
177	Amyloid- β^2 (1-42) peptide induces rapid NMDA receptor-dependent alterations at glutamatergic synapses in the entorhinal cortex. <i>Neurobiology of Aging</i> , 2021, 105, 296-309.	1.5	6
178	Transferrin-Pep63-liposomes accelerate the clearance of A β^2 and rescue impaired synaptic plasticity in early Alzheimer's disease models. <i>Cell Death Discovery</i> , 2021, 7, 256.	2.0	13
179	Distinct types of amyloid- β^2 oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 1594-1608.	1.2	15
180	p38 MAPK-mediated loss of nuclear RNase III enzyme Drosha underlies amyloid beta-induced neuronal stress in Alzheimer's disease. <i>Aging Cell</i> , 2021, 20, e13434.	3.0	14
181	Role of Ionotropic Glutamate Receptors in Neurodegenerative and Other Disorders. , 2021, , 1-29.		0

#	ARTICLE	IF	CITATIONS
183	Pathogenesis of Abeta Oligomers in Synaptic Failure. <i>Current Alzheimer Research</i> , 2013, 10, 316-323.	0.7	77
184	PNU282987 inhibits amyloid β aggregation by upregulating astrocytic endogenous β -crystallin and HSP70 via regulation of the β 7AChR, PI3K/Akt/HSF1 signaling axis. <i>Molecular Medicine Reports</i> , 2020, 22, 201-208.	1.1	13
185	Pathophysiological Ionotropic Glutamate Signalling in Neuroinflammatory Disease as a Therapeutic Target. <i>Frontiers in Neuroscience</i> , 2021, 15, 741280.	1.4	11
186	Jacob, a Synapto-Nuclear Protein Messenger Linking N-methyl-D-aspartate Receptor Activation to Nuclear Gene Expression. <i>Frontiers in Synaptic Neuroscience</i> , 2021, 13, 787494.	1.3	7
187	Synaptic dysfunction in early phases of Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.0	27
188	Amyloid- β oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: Relevance to the synapse pathology of Alzheimer's disease. <i>Neuroscience Research</i> , 2022, , .	1.0	12
189	Differential vulnerability of hippocampal CA3-CA1 synapses to $A\beta$. <i>Acta Neuropathologica Communications</i> , 2022, 10, 45.	2.4	4
203	Involvement of cholesterol and β -amyloid in the initiation and progression of Alzheimer's disease. , 2022, , 715-745.		0
204	Bioactive human Alzheimer brain soluble $A\beta$: pathophysiology and therapeutic opportunities. <i>Molecular Psychiatry</i> , 2022, 27, 3182-3191.	4.1	14
205	EVALUATION OF ANTAGONIST ACTIVITY OF IFENPRODIL AND THEIR ANALOGOUS AGAINST GLUN1/GLUN2B USING IN SILICO MOLECULAR DOCKING AND ABSORPTION-DISTRIBUTIONMETABOLISM- EXCRETION TOXICITY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 34-40.	0.3	0
206	β -secretase promotes <i>Drosophila</i> postsynaptic development through the cleavage of a Wnt receptor. <i>Developmental Cell</i> , 2022, 57, 1643-1660.e7.	3.1	14
207	Synapse pathology in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 13-23.	2.3	30
208	Sphingosine 1-phosphate attenuates neuronal dysfunction induced by amyloid β oligomers through endocytic internalization of NMDA receptors. <i>FEBS Journal</i> , 2023, 290, 112-133.	2.2	4
209	β Pathology and Neuron-Glia Interactions: A Synaptocentric View. <i>Neurochemical Research</i> , 2023, 48, 1026-1046.	1.6	12
210	Metaplasticity and non-invasive brain stimulation: the search for new biomarkers and directions for therapeutic neuromodulation. <i>Annals of Clinical and Experimental Neurology</i> , 2022, 16, 74-82.	0.1	1
211	Altered Functional Connectivity of Basal Ganglia in Mild Cognitive Impairment and Alzheimer's Disease. <i>Brain Sciences</i> , 2022, 12, 1555.	1.1	6
212	Synaptic degeneration in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2023, 19, 19-38.	4.9	84
213	Role of Ionotropic Glutamate Receptors in Neurodegenerative and Other Disorders. , 2022, , 1969-1997.		0

#	ARTICLE	IF	CITATIONS
214	Jacobâ€induced transcriptional inactivation of <sc>CREB</sc> promotes AÎ²â€induced synapse loss in Alzheimer's disease. EMBO Journal, 2023, 42, .	3.5	9
221	Targeting metaplasticity mechanisms to promote sustained antidepressant actions. Molecular Psychiatry, 0, , .	4.1	1
223	The glutamatergic system in Alzheimerâ€™s disease: a systematic review with meta-analysis. Molecular Psychiatry, 0, , .	4.1	0